{
    "clinical_study": {
        "@rank": "79067", 
        "arm_group": [
            {
                "arm_group_label": "ARM 1: L19IL2 + Dacarbazine", 
                "arm_group_type": "Experimental", 
                "description": "L19IL2 starting at 480,000 IU/kg  until MTD is reached (in steps of 160,000 IU/kg, i.e., 0.48; 0.64; 0.80 MioIU/kg)\nDacarbazine  1000 mg/m2 (fixed dose)"
            }, 
            {
                "arm_group_label": "ARM 2: Dacarbazine", 
                "arm_group_type": "Active Comparator", 
                "description": "Dacarbazine  1000 mg/m2 (fixed dose)"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase II clinical study is an open-label, multicenter study of L19IL2 in combination\n      with Dacarbazine in patients with metastatic melanoma.\n\n      The study is divided in two parts: a phase IIa part, designed to establish the recommended\n      dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine, as\n      well as to determine the preliminary tolerability profile; the second phase IIb part\n      evaluates the objective response rate (ORR) including a randomized study with a fixed dose\n      of Dacarbazine with or without L19IL2, dosed at the RD determined in phase IIa."
        }, 
        "brief_title": "A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Melanoma Stage IV", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "Dose limiting toxicity will be assessed during the dose-escalation part of Phase IIa from\n      day 1 through day 21 of the first cycle.\n\n      Response will be measured using RECIST criteria every 6 weeks (after every 2 cycles of\n      treatment). Patients with stable or responding disease at each assessment may receive\n      additional treatment for a maximum of 6 cycles of induction. Patients with stable or\n      responding disease after induction may receive L19IL2 (without dacarbazine) every 2 weeks as\n      maintenance therapy.\n\n      Tumor expression of ED-B FN and tumor uptake of L19IL2 and of Dacarbazine will be assessed\n      via immunohistochemistry and/or other methods deemed appropriate on tumor tissue biopsies.\n      Tumor biopsy will be performed on superficial accessible cutaneous and/or subcutaneous\n      lesions only. Tumor biopsy will be considered optional and will not preclude patient entry\n      on to study should the patient refuse.\n\n      Pharmacokinetics of L19IL2, Dacarbazine and AIC will be assessed from serial blood samples\n      using standard methods.\n\n      Overall response rate, PFS, survival rate at 6 and 12 months, and overall survival time for\n      all patients and separately for the patients in the Phase IIb part will be assessed using\n      standard methods."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18-70 years of age, inclusive\n\n          2. Must have histologically or cytologically confirmed cutaneous metastatic melanoma\n             (Stage IV). For the Phase II part only patients with Stage IV M1a or M1b will be\n             enrolled.\n\n          3. Must have measurable disease according to Response Evaluation Criteria in Solid\n             Tumors (RECIST 1.1) as identified by CT or MRI scan within 28 days before the first\n             study drug administration.\n\n          4. Baseline LDH within normal range\n\n          5. Maximal 1 line of previous systemic treatment for metastatic disease (prior adjuvant\n             melanoma therapy, e.g., IFN, is permitted.\n\n          6. For women of childbearing potential, a negative pregnancy test within 72 hours prior\n             to the first dose of study treatment.\n\n          7. Women with reproductive potential must be willing to practice acceptable methods of\n             birth control during the study and for up to 12 weeks after the last dose of study\n             medication.\n\n          8. Men with reproductive potential must be willing to practice acceptable methods of\n             birth control during the study and for up to 12 weeks after the last dose of study\n             medication.\n\n          9. Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n\n         10. Life expectancy of at least three months\n\n         11. Adequate organ function: serum creatinine \u2264 1.5 x ULN, total bilirubin \u2264 30 mM/L (or\n             mg/dL, \u2264 2.0 mg/dL), hepatic transaminases \u2264 2.5 x ULN, alkaline phosphatase \u2264 2.5 x\n             ULN.\n\n         12. ANC count \u2265 1.5 x 10^9/L, platelet count \u2265 100 x 10^9/L, hemoglobin > 9 g/dL\n\n         13. Normal 12-lead ECG and normal bidimensional echocardiogram or MUGA\n\n         14. All toxic effects of prior therapy must have resolved to grade \u22641 unless otherwise\n             specified above\n\n         15. Willing and able to give written informed consent.\n\n        Exclusion Criteria:\n\n          1. Pregnant or breastfeeding female\n\n          2. Primary ocular melanoma\n\n          3. Primary mucosal melanoma\n\n          4. Use of any investigational or other anti-cancer drug within 28 days or 5 half-lives,\n             whichever is longer, preceding the first dose of DTIC and L19-IL2\n\n          5. Prior radiation to a target lesion, unless there has been clear progression of the\n             lesion since radiotherapy\n\n          6. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or\n             Hepatitis C Virus (HCV) infection\n\n          7. History or clinical evidence of brain metastases or leptomeningeal disease\n\n          8. Any other malignancy from which the patient has been disease-free for less than 5\n             years, with the exception of adequately treated and cured basal or squamous cell skin\n             cancer, superficial bladder cancer, or carcinoma in situ of the cervix\n\n          9. Treatment with DTIC within 6 months before start of study\n\n         10. Treatment with Ipilimumab within 6 months before start of study\n\n         11. Hypersensitivity to DTIC\n\n         12. Concomitant use of drugs known to alter cardiac conduction\n\n         13. Chronic use of corticosteroids used in the management of cancer or non-cancer-related\n             illness\n\n         14. Unstable or serious concurrent uncontrolled medical conditions\n\n         15. Inadequately controlled cardiac arrhythmias including atrial fibrillation\n\n         16. History of acute or subacute coronary syndromes including myocardial infarction,\n             unstable or severe stable angina pectoris\n\n         17. Heart insufficiency > grade II NYHA criteria\n\n         18. Uncontrolled hypertension\n\n         19. Ischemic peripheral vascular disease\n\n         20. Active infection or incomplete wound healing.\n\n         21. History or evidence of active autoimmune disease.\n\n         22. Known history of allergy to intravenously administered proteins/peptides/antibodies\n\n         23. History of organ allograft.or allogeneic peripheral blood progenitor cell or bone\n             marrow transplantation\n\n         24. Major trauma including surgery within 4 weeks prior to entering the study.\n\n         25. Any underlying medical or psychiatric condition which in the opinion of the\n             investigator will make administration of study drug hazardous or hinder the\n             interpretation of study results (e.g. AE).\n\n         26. Melanoma patients with BRAF 600 E mutation who are amenable to receive approved\n             treatments able to extend overall survival."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076646", 
            "org_study_id": "PH-L19IL2DTIC-04-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARM 1: L19IL2 + Dacarbazine", 
                "description": "L19IL2:  Intravenous (IV) infusion of  on days 1, 8 and 15 of each 21-day cycle over 3 hours via automated device (perfusor).\nDacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle,administered 30 minutes after the end of the L19IL2 infusion.\nL19IL2 starting dosage:  480,000 IU/kg  increasing until MTD is reached (in steps of 160,000 IU/kg, i.e., 0.48; 0.64; 0.80 MioIU/kg) Dacarbazine  dosage: 1000 mg/m2 (fixed dose)\nTreatment will terminate at the earliest of the following: disease progression, unacceptable toxicity, withdrawal of consent. Patients will be followed for one year from the start of the treatment or until withdrawal of consent, whichever occurs first.", 
                "intervention_name": "Arm 1: L19IL2 + Dacarbazine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ARM 2: Dacarbazine", 
                "description": "Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose)\nTreatment will terminate at the earliest of the following: disease progression, unacceptable toxicity, withdrawal of consent. Patients will be followed for one year from the start of the treatment or until withdrawal of consent, whichever occurs first. until disease progression, unacceptable toxicity, withdrawal of consent, whichever occurs first.", 
                "intervention_name": "Arm 2: Dacarbazine", 
                "intervention_type": "Drug", 
                "other_name": "DETICENE\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Dacarbazine", 
                "Interleukin-2"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Interleukin", 
            "IL2", 
            "monoclonal", 
            "antibody", 
            "cytokine", 
            "Dacarbazine", 
            "metastatic", 
            "melanoma", 
            "tumor targeting", 
            "Dose definition", 
            "L19"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Claus Garbe, Prof. M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Tuebingen", 
                        "country": "Germany"
                    }, 
                    "name": "University Hospital"
                }, 
                "investigator": {
                    "last_name": "Claus Garbe, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michele Maio, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Universitaria Senese"
                }, 
                "investigator": {
                    "last_name": "Michele Maio, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma", 
        "overall_contact": {
            "last_name": "Leonardo Giovannoni, Dr", 
            "phone": "(0039) 0577 588 539"
        }, 
        "overall_official": [
            {
                "affiliation": "University Hospital Tuebingen (Germany)", 
                "last_name": "Claus Garbe, Prof. M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Azienda Ospedaliera Universitaria Senese, Siena (Italy)", 
                "last_name": "Michele Maio, Dr.med.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: National Institute of Health (Instituto Superiore di Sanit\u00e0)", 
                "Italy: Ethics Commissions", 
                "Germany: Paul-Ehrlich-Institut", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Establish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study", 
                "measure": "Phase I: Establish the maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "description": "evaluation of the best objective response rate (BORR)", 
                "measure": "Phase II: evaluation of the antitumor activity", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076646"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate antitumor activity in terms of confirmed best objective response rate (BORR), duration of overall response, disease control rate, progression free survival (PFS) and overall survival (OS).", 
                "measure": "Phase I: evaluation of the antitumor activity", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Evaluation of the type and the number of adverse events eventually present", 
                "measure": "Phase II: Safety and Tolerability of L19-IL2 in combination with DTIC vs DTIC alone.", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Investigate the duration of overall response, disease control rate, progression free survival (PFS) and overall survival (OS).", 
                "measure": "Phase II: Treatment efficacy", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "Philogen S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philogen S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}